10:24 AM
Nov 09, 2018
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Earnings roundup: Alnylam off after first peek at Onpattro sales

Shares of at least three companies moved double digits on Nov. 7 after the companies provided 3Q18 financial results, with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) sliding after reporting sales for newly launched amyloidosis drug Onpattro patisiran and discontinuation of a Phase II program for atypical hemolytic uremic syndrome (aHUS).

Alnylam lost $10.23 (12%) to $76.05 following the report, representing a market cap loss of just over $1 billion. Meanwhile, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was down $24 (15%) to $140.41 after reporting weaker than expected sales, while diagnostic company Genomic Health Inc. (NASDAQ:GHDX) touched an all-time intraday high of $92.18 after reporting its numbers.

Alnylam said Onpattro generated $0.5 million in...

Read the full 521 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >